Review article: Tegaserod - The global experience

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 7, 2004, Pages 15-19

  Chey, W D ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DIETARY FIBER; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FLATULENCE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SECRETION; HEADACHE; HUMAN; INTESTINE TRANSIT TIME; IRRITABLE COLON; NONHUMAN; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PRIORITY JOURNAL; SENSORY NERVE; SYMPTOM;

EID: 10644269342     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02181.x     Document Type: Conference Paper

References (16)

1. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97: S7-26.
2. Gershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disorders 2003; 3(Suppl. 2): S25-34.
3. Chey WD. Tegaserod and other serotonergic agents: What is the evidence? Rev Gastroenterol Disorders 2003; 3: S35-40.
4. Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001; 15: 777-89.
5. Muller-Lissner S, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating, and constipation. Aliment Pharmacol Ther 2001; 15: 1655-66.
6. Krumholz S, Tangh J, Schmitt C, Heggland J, Shi Y, Ruegg PC. The 5-HT4 receptor partial agonist tegaserod improves abdominal bloating and altered stool consistency in irritable bowel syndrome. Gut 1999; 45(Suppl. V): A260 (Abstract).
7. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
8. van Zanten SJOV, Talley NJ, Bytzer P, et al. Design of treatment trials for the functional gastrointestinal disorders. In: Drossman DA, ed. Rome II: The Functional Gastrointestinal Disorders, 2nd edn. McLean, VA: Degnon Associates, 2000: Chapter 11.
9. Tougas G, Snape WJ Jr, Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16: 1701-8.
10. Lin SR, Zhou LY, Liu XG, et al. Tegaserod provides rapid, effective relief of abdominal pain/discomfort, bloating and constipation in Chinese patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2003; 124 (4 Suppl. 1): A137(Abstract).
11. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671-6.
12. Nyhlin H, Bang C, Eisborg L, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004; 39: 119-126.
13. Uscanga-Dominguez L, Cohen Munoz V, on behalf of the Latin America Investigator Group on Tegaserod. Relapse of symptoms following withdrawal of tegaserod treatment in irritable bowel syndrome with constipation. Gastroenterology 2003; 124(4 Suppl. 1): A571(Abstract).
14. Bardhan KD, Forbes A, Marsden C, et al. Continuous treatment with tegaserod provides improved control of IBS-C symptoms. Gut 2003; 52(Suppl. VI): A93(Abstract).
15. Müller-Lissner SA, Holtman G, Loeffler H, Ruegg P. Tegaserod is effective in the retreatment of irritable bowel syndrome with constipation. Gastroenterology 2003; 124(4 Suppl. 1): A574(Abstract).
16. Shah SHA, Jafri SW, Gul M, et al. An open-label study to determine the efficacy and tolerability of tegaserod in the treatment of constipation-dominant irritable bowel syndrome (IBS-C). Gastroenterology 2003; 124: A533(Abstract).